[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Second Affiliated Hospital, School of Medicine, Zhejiang University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":564},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,427,0,25,[9,46,70,93,118,141,159,173,193,211,233,253,275,304,324,349,369,388,414,435,459,478,496,516,536],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100632638","phase-1-safety-and-efficacy-of-second-infusion-of-fap-icdc-in-end-stage-dilated-cardiomyopathy-100632638",false,"NCT07516288","Safety and Efficacy of Second Infusion of FAP iCDC in End-stage Dilated Cardiomyopathy","Safety and Efficacy of Second Infusion of Autologous Immunosuppressive CAR-DC Targeting FAP in the Treatment of End-stage Dilated Cardiomyopathy","Inclusion Criteria:\n\n* ≥18 years and ≤75 years of age, with a confirmed diagnosis of dilated cardiomyopathy.\n* Patients who previously received a single infusion of immunosuppressive CAR-DC (iCDC) therapy and, at 6 months after the first treatment, failed to maintain improvement in cardiac function, with cardiac function declining to baseline levels prior to treatment. These patients should have persistent heart failure symptoms that cannot be adequately improved, with left ventricular ejection fraction (LVEF) \\\u003C35%, New York Heart Association (NYHA) functional class III-IV, and INTERMACS profile 3-6.\n* Able to verbally confirm understanding of the risks, benefits, and alternative treatment options of the second administration of iCDC therapy, and willing to participate in the study. The participant or his\u002Fher legal representative must provide written informed consent prior to enrollment.\n* Hematocrit \\>30%, lymphocyte count \\>0.5 × 10⁹\u002FL, and platelet count \\>60 × 10⁹\u002FL.\n\nExclusion Criteria:\n\n* Severe renal failure or requirement for renal dialysis, or serum creatinine \\>2.5 mg\u002FdL.\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels greater than 5.0 times the upper limit of normal (ULN), or total bilirubin \\>3 mg\u002FdL.\n* Presence of active infections at screening, including: Active hepatitis B infection with hepatitis B virus DNA \\>1000 copies\u002FmL by PCR testing; Hepatitis C virus infection; Syphilis; Human immunodeficiency virus (HIV) infection; Uncontrolled systemic fungal, bacterial, viral, or other pathogenic infections.\n* Severe hemodynamic instability (e.g., shock).\n* Known contraindications to the investigational product or study-related procedures.","ALL","18 Years","75 Years",{"count":21,"type":22},5,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This study aims to evaluate the safety and preliminary efficacy of a second administration of fibroblast activation protein (FAP)-targeted immunosuppressive chimeric antigen receptor dendritic cells (CAR-DC) in patients with end-stage dilated cardiomyopathy.\n\nPrevious clinical research has shown that single-dose CAR-DC therapy is safe and may provide clinical benefit. However, some patients experience recurrent worsening of heart function after initial treatment. This study will assess whether a second CAR-DC infusion is safe and whether it can further improve cardiac function in this patient population.",[28,29],"Dilated Cardiomyopathy (DCM)","Heart Failure",[31,32],"end-stage dilated cardiomyopathy","FAP immunosuppressive CAR-DC","RECRUITING","2026-07-01",{"date":36,"type":37},"2026-07-02","ACTUAL",{"date":39,"type":37},"2026-05-11",{"date":41,"type":22},"2027-12-31",{"name":43,"class":44},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":45},"100631785","phase-1-safety-and-efficacy-of-fap-icdc-in-ischemic-cardiomyopathy-100631785","NCT07505199","Safety and Efficacy of FAP iCDC in Ischemic Cardiomyopathy","Safety and Efficacy of FAP-Targeted Immunosuppressive CAR-DC in the Treatment of Ischemic Cardiomyopathy","Inclusion Criteria:\n\n* Age ≥18 years and ≤75 years.\n* Diagnosis of ischemic cardiomyopathy, with at least 3 months of optimized guideline-directed medical therapy (GDMT) at maximally tolerated doses; left ventricular ejection fraction (LVEF) \\\u003C35%; New York Heart Association (NYHA) functional class III-IV.\n* Ability to understand the risks, benefits, and treatment alternatives of immunoregulatory CAR-DC therapy, and willingness to participate in the study; the patient or his\u002Fher legally authorized representative must provide written informed consent prior to study enrollment.\n* Adequate hematologic function defined as: hematocrit \\>30%, lymphocyte count \\>0.5 × 10⁹\u002FL, and platelet count \\>60 × 10⁹\u002FL.\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C1 year due to non-cardiac conditions.\n\nCardiac resynchronization therapy (CRT) implantation within 3 months prior to enrollment or planned CRT implantation.\n\nPercutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within 3 months prior to enrollment OR plan to PCI.\n\nPresence of non-ischemic cardiomyopathy, including but not limited to dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic cardiomyopathy, peripartum cardiomyopathy, inflammatory or immune-mediated cardiomyopathy, metabolic or genetic cardiomyopathy, or cardiomyopathy secondary to moderate-to-severe valvular heart disease, congenital heart disease, or other non-ischemic etiologies.\n\nPersistent hemodynamic instability.\n\nEnd-stage renal disease (eGFR \\\u003C25 mL\u002Fmin\u002F1.73 m²) requiring or receiving renal replacement therapy (hemodialysis or peritoneal dialysis).\n\nActive autoimmune disease requiring immunosuppressive therapy.\n\nHistory of malignancy.\n\nActive infection, including but not limited to active hepatitis B (HBV DNA \\>1000 copies\u002FmL by PCR), hepatitis C, syphilis, or human immunodeficiency virus (HIV) infection, or uncontrolled systemic fungal, bacterial, viral, or other infections.\n\nPregnant women.\n\nKnown contraindications to the investigational product or study-related procedures.",{"count":54,"type":22},30,[25],"This study aims to evaluate the safety and efficacy of fibroblast activation protein (FAP)-targeted autologous immunosuppressive chimeric antigen receptor dendritic cell (iCDC) therapy in patients with ischemic cardiomyopathy, and to explore its potential as a novel therapeutic strategy for this disease.",[58,59],"Ischemic Cardiomyopathy","Cell Therapy",[61,62,63],"ischemic cardiomyopathy","dendritic cell","immune tolerance",{"date":36,"type":37},{"date":66,"type":37},"2026-05-21",{"date":68,"type":22},"2029-04-01",{"name":43,"class":44},{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":77,"targetDuration":79,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":45},"100643859","bone-cancer-surgery-prospective-database-100643859","NCT07669103","Bone Cancer Surgery Prospective Database","Bone Cancer Surgery Prospective Database on Perioperative Characteristics and Postoperative Complications","Inclusion Criteria:\n\n1. Clinical diagnosis of bone cancer\n2. Scheduled to undergo elective bone cancer resection surgery\n\nExclusion Criteria:\n\n1. Unable to comply with follow-up\n2. declined participation in the study",{"count":78,"type":22},400,"3 Years","OBSERVATIONAL","According to the Global Burden of Disease Report, the number of cancer patients worldwide is increasing year by year. In 2023, there were a total of 18.5 million newly confirmed cases of malignant tumors worldwide, and it is expected to grow to 30.5 million cases by 2050. Among them, the number of new cases of malignant tumors of bone and articular cartilage increased by 86.4% from 1990 to 2023. Meanwhile, bone is a particularly common site for tumor metastasis, and almost half of cancer patients are at risk of developing bone metastasis. Surgical resection is the main treatment method for both primary and secondary bone cancer. For patients with bone cancer, the main goal of surgical treatment is to maintain the patient's function and mobility by relieving pain, preventing impending fractures and\u002For nerve compression, or stabilizing pathological fractures. Surgery for bone cancer often requires extensive exploration, osteotomy, and prosthetic reconstruction, resulting in significant surgical trauma. The incidence of postoperative complications remains high. The occurrence of postoperative complications can increase patient pain, prolong hospitalization time, increase medical costs, and even endanger life. Therefore, reduction of complications and optimizing perioperative management are key issues that urgently need to be addressed in clinical practice.",[83],"Bone Cancer Surgery","NOT_YET_RECRUITING","2026-06-24",{"date":87,"type":37},"2026-06-29",{"date":89,"type":22},"2026-07",{"date":91,"type":22},"2028-07",{"name":43,"class":44},{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":105,"conditions":106,"keywords":111,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":115,"leadSponsor":117,"locationsCount":45},"100644018","the-effect-of-liposomal-bupivacaine-erector-spinae-plane-block-100644018","NCT07667439","The Effect of Liposomal Bupivacaine Erector Spinae Plane Block","The Effect of Liposomal Bupivacaine Erector Spinae Plane Block on Postoperative Pain in Patients Undergoing Open Upper Abdominal Surgery: A Randomized, Controlled, Double-Blind Trial","Inclusion Criteria:\n\n1. Patients scheduled for elective open upper abdominal surgery, including open liver, gastric and pancreatic surgery.\n2. Patients receiving general anesthesia with tracheal intubation.\n3. Aged from 18 to 80 years old.\n4. Patients with American Society of Anesthesiologists (ASA) physical status class Ⅰ-Ⅲ.\n5. Patients who can understand the trial content, are willing to strictly follow the clinical research protocol and complete the trial, and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. Patients complicated with severe primary diseases of the lung, liver, kidney, cardiovascular system and hematopoietic system.\n3. Bleeding tendency or coagulation dysfunction, defined as international normalized ratio (INR) ≥ 1.4, activated partial thromboplastin time \\> 38 s, or platelet count \\\u003C 80×10⁹\u002FL.\n4. Patients with aggravated cardiac diseases (complex congenital heart disease, heart failure and valvular disease) or pulmonary insufficiency.\n5. Skin infection at the puncture site for erector spinae plane block (ESPB).\n6. Previous history of neurological or psychiatric diseases, with inability to read, understand and communicate.\n7. Current obstructive or restrictive pulmonary disease.\n8. Patients with BMI greater than 30 kg\u002Fm².\n9. Drug abuse, long-term regular use of analgesics, or allergy to the study drugs.\n10. Patients who refuse to provide informed consent.\n11. Those enrolled in other randomized controlled trials simultaneously or with other conditions unsuitable for participation in this trial.","80 Years",{"count":102,"type":22},148,[104],"NA","This is a single-center, randomized, controlled, double-blind clinical trial. A total of 148 patients undergoing elective open upper abdominal surgery will be included and randomly assigned 1:1 to receive ultrasound-guided erector spinae plane block with liposome bupivacaine plus bupivacaine hydrochloride or bupivacaine hydrochloride alone. The primary outcome is the AUC of resting pain scores from 0 to 72 hours postoperatively. This study aims to evaluate the analgesic efficacy and safety of liposome bupivacaine and provide a long-acting and safe postoperative analgesia strategy.",[107,108,109,110],"Liposome Bupivacaine","Erector Spinae Plane Block","Postoperative Analgesia","Randomized Controlled Trial",[107,108,109,110],{"date":113,"type":37},"2026-06-25",{"date":34,"type":22},{"date":116,"type":22},"2027-02-05",{"name":43,"class":44},{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":45},"100644657","small-rna-trf-31-changes-in-patients-with-age-related-cataract-100644657","NCT07672899","Small RNA tRF-31 Changes in Patients With Age-Related Cataract","Biphasic Dynamics of the tRNA-derived Small RNA tRF-31 Set the Lens Oxidative Survival Threshold by Restraining HIPK2-mediated Dual-track Lethality in Age-related Cataract","Inclusion Criteria:\n\nPatients older than 18 years. Clinically diagnosed with age-related cataract (ARC) and have clear surgical indications for routine phacoemulsification combined with intraocular lens (IOL) implantation. Scheduled to undergo cataract extraction and intraocular lens implantation. Completed routine preoperative corneal endothelial specular microscopy, providing objective data including cell density, coefficient of variation of cell area, and the proportion of hexagonal cells. Provided signed written informed consent.\n\nExclusion Criteria:\n\nHistory of ocular trauma, glaucoma, episodes of active uveitis, or previous intraocular surgery. Presence of severe systemic diseases rendering the patient unsuitable for surgery. Poor patient compliance or coexisting psychiatric disorders. Severe systemic metabolic syndromes (e.g., diabetes). Diagnosis of high myopia. Current participation in other clinical trials or likelihood of being lost to follow-up.",{"count":126,"type":22},200,"The goal of this observational study is to evaluate the expression characteristics and clinical relevance of the tRF-31\u002FHIPK2 signaling axis in adults over 18 years old with age-related cataract (ARC). The main questions it aims to answer are: Is there a correlation between the relative expression levels of tRF-31 and its target gene HIPK2 in the anterior lens capsule and the clinical severity (Emery-Little grading system) of age-related cataracts? Does oxidative stress in the anterior segment microenvironment have a potential bystander effect on the state of the corneal endothelium? Participants will:Undergo routine preoperative ophthalmologic examinations, including visual acuity tests, slit-lamp photography, and corneal endothelial cell counting. Undergo standard cataract surgery (phacoemulsification combined with intraocular lens implantation) as part of their regular medical care. Allow researchers to collect and analyze their anterior lens capsule tissue, which is routinely removed and typically discarded as medical waste during the standard continuous curvilinear capsulorhexis (CCC) step of the surgery.",[129],"Cataract",[131,132,133],"age-related cataract","oxidative stress","tRNA-derived small RNA","2026-06-23",{"date":87,"type":37},{"date":137,"type":37},"2026-06-17",{"date":139,"type":22},"2026-09-16",{"name":43,"class":44},{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":4},"100643953","developmentandapplication-of-a-single-feature-recognition-model-for-heart-failure-based-onartificial-intelligence-optimization-algorithms-100643953","NCT07667452","DevelopmentandApplication of a Single Feature Recognition Model for Heart Failure Based onArtificial Intelligence Optimization Algorithms","Inclusion Criteria:\n\n* Age ≥ 18 years old;\n* Body mass index \\\u003C 35 kg\u002Fm2;\n* Diagnosed with heart failure: according to \"Chinese Guidelines for Diagnosis and Treatment of Heart Failure 2024\", \"2021 ESC Guidelines for Diagnosis and Treatment of Acute and Chronic Heart Failure\", and \"2022 AHA\u002FACC\u002FHFSA Guidelines for Management of Heart Failure\";\n* NYHA classification II - IV;\n* Able to fully understand the purpose and process of the trial and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* There are physical disabilities that prevent safe and thorough testing;\n* There are open wounds on the chest skin or the skin is allergic to the patches;\n* There is a large amount of pericardial effusion, pericardial tamponade, pleural friction rub, pneumothorax, and a large amount of pleural effusion, which may affect data collection;\n* The patient has severe comorbidities or unstable condition, which may interfere with data collection during the study period;\n* Other situations where the investigator believes the subject is not suitable to participate in this trial, such as those that may increase the risk of the trial, affect the subject's compliance with the protocol, or affect the subject's ability to complete the trial due to physical or psychological diseases or conditions.",{"count":148,"type":22},50,"The goal of this observational study is to develop and validate a single-feature artificial intelligence algorithm based on data from a wearable ECG patch in patients with heart failure (HF). The main question it aims to answer is:\n\nDoes the algorithm, using synchronized ECG and accelerometer signals from the patch, achieve accurate detection of heart sounds (S1, S2, and in some patients S3, S4) compared to the Eko CORE500 digital stethoscope in patients with acute exacerbation of HF?\n\nParticipants with confirmed HF (NYHA class II-IV) will undergo two 2-minute sessions of simultaneous ECG patch and digital stethoscope recordings, followed by standard 12-lead ECG. Data will be used for algorithm training and validation, with the primary endpoint being the sensitivity and specificity of heart sound detection against the reference device.",[151,152],"Cardiac Sound","Heart Failure - NYHA II - IV",{"date":113,"type":37},{"date":155,"type":22},"2026-06-01",{"date":157,"type":22},"2027-05-31",{"name":43,"class":44},{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":171,"leadSponsor":172,"locationsCount":4},"100643942","clinical-study-on-the-optimization-algorithm-of-single-lead-electrocardiogram-conduction-interval-100643942","NCT07667465","Clinical Study on the Optimization Algorithm of Single Lead Electrocardiogram Conduction Interval","Inclusion Criteria:\n\n* Age ≥18 years;\n* body mass index \\\u003C 35 kg\u002Fm2;\n* with stable sinus rhythm;\n* PR interval, QRS duration, or QT interval were stable and at least one was outside the normal range;\n* fully understood the purpose and procedure of the trial and voluntarily signed an informed consent form.\n\nExclusion Criteria:\n\n* There are physical disabilities that prevent safe and thorough testing;\n* Open wounds on the chest skin or skin allergy to patches;\n* Post-implantation of temporary or permanent cardiac pacemaker, ICD, CRT or CRTD, after artificial heart valve replacement, with large amounts of pericardial effusion, pericardial tamponade, pleural friction rub, pneumothorax, large amounts of pleural effusion, etc., which may affect data collection;\n* The patient has severe comorbidities or unstable condition, which may interfere with data collection during the study period;\n* Other situations where the researcher considers the subject unsuitable to participate in this trial, such as potentially increasing the risk of the trial, affecting the subject's compliance with the protocol, or affecting the subject's ability to complete the trial due to physical or psychological diseases or conditions.",{"count":148,"type":22},"The goal of this observational study is to develop and validate an optimization algorithm for single-lead ECG conduction intervals using a wearable ECG patch combined with synchronized heart sound data, and to evaluate its agreement with the clinical gold standard (12-lead ECG) in adult patients. The main question it aims to answer is:\n\nDoes the optimized algorithm, based on ECG patch and synchronous heart sound recordings, improve the detection accuracy of PR interval, QRS duration, and QT interval compared to standard 12-lead ECG?\n\nParticipants (age ≥18 years, BMI \\\u003C35 kg\u002Fm², stable sinus rhythm with at least one abnormal conduction interval) will undergo two 2-minute sessions of simultaneous ECG patch and digital stethoscope recordings, followed by standard 12-lead ECG. Data will be used for algorithm training and validation, with primary endpoints being the sensitivity and specificity of the optimized intervals against the gold standard.",[168],"Conduction of Electrocardiogram",{"date":113,"type":37},{"date":155,"type":22},{"date":157,"type":22},{"name":43,"class":44},{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":190,"leadSponsor":192,"locationsCount":45},"100644344","construction-of-a-prospective-cohort-database-for-the-perioperative-period-of-cardiac-surgery-100644344","NCT07662317","Construction of a Prospective Cohort Database for the Perioperative Period of Cardiac Surgery","Inclusion Criteria:\n\n* Patients undergoing cardiac surgery from May 1, 2026 to December 31, 2031\n\nExclusion Criteria:\n\n* Refusal to provide informed consent",{"count":180,"type":22},10000,"Cardiovascular disease (CVD) is the leading cause of global morbidity and mortality, with its prevalence increasing significantly from 1990 to 2019. Establishing a comprehensive cardiac surgery database is crucial for exploring perioperative prognostic factors and improving clinical outcomes.\n\nThis muti-center, prospective observational study aims to construct a prospective cohort database for perioperative cardiac surgery. We plan to enroll adult patients who undergo cardiac surgery with cardiopulmonary bypass at the Second Affiliated Hospital of Zhejiang University and other hospitals from May 1, 2026 to December 31, 2031. Multi-dimensional perioperative data, including laboratory tests, hemodynamics, intraoperative echocardiography, and perioperative medications, will be collected and integrated, along with epidemiological data, clinical diagnosis and treatment information, multimodal data, and follow-up outcomes. An interconnected big data sharing platform will also be built.\n\nThis database will provide a valuable resource for multi-level researches such as perioperative risk assessment, individualized prevention, precise diagnosis and treatment, and therapeutic efficacy monitoring. It will also help optimize surgical and perioperative management, improve the quality of cardiac surgery, and provide evidence for the refinement of China's healthcare system, ultimately enhancing perioperative safety and rehabilitation efficiency of patients.",[183,184,185,186],"Valve Heart Disease","Coronary Artery Disease","Coronary Heart Disease","Aortic Diseases","2026-06-22",{"date":134,"type":37},{"date":113,"type":22},{"date":191,"type":22},"2032-05-31",{"name":43,"class":44},{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":23,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":208,"leadSponsor":210,"locationsCount":45},"100643930","acute-normovolemic-hemodilution-in-bone-cancer-surgery-100643930","NCT07669155","Acute Normovolemic Hemodilution in Bone Cancer Surgery","The Effect of Acute Normovolemic Hemodilution on Requirement of Allogeneic Red Blood Cell in Patients Undergoing Bone Cancer Surgery","Inclusion Criteria:\n\n1. age 18 more than years;\n2. undergoing elective bone cancer resection surgery;\n3. preoperative hemoglobin ≥12 g\u002FdL;\n\nExclusion Criteria:\n\n1. using a tourniquet;\n2. BMI\\\u003C18.5 Kg\u002Fm\\^2;\n3. international normalized ratio (INR) \\>1.5 or platelet count \\\u003C100 × 10\\^9\u002FL;\n4. cardiopulmonary insufficiency;\n5. hepatic and renal dysfunction;\n6. active infectious disease;\n7. allergy to colloid solution;\n8. pregnancy;\n9. declined participation in the study or declined blood transfusion",{"count":201,"type":22},420,[104],"Malignant bone tumors often lead to skeletal complications, known as skeletal related events (SRE). These complications mainly include pathological fractures, severe pain, and spinal cord compression. Typically, SRE reduces overall survival rates and is associated with loss of mobility and social functioning, decreased quality of life, and significantly increased healthcare costs. Surgical resection is an important means of treating malignant bone tumors. The main goal of surgical treatment is to maintain the patient's function and mobility by relieving pain, preventing impending fractures and\u002For nerve compression, or stabilizing pathological fractures. Surgery for malignant bone tumors often requires extensive exploration, osteotomy, and prosthetic reconstruction. The surgery involves significant trauma and excessive bleeding from the wound. Therefore, there is a significant risk of perioperative blood loss and transfusion during surgery for malignant bone tumors. However, blood transfusion also brings transfusion related risks to patients, increases the incidence of postoperative complications, and increases the healthcare burden on patients and society. Acute normovolemic hemodilution (ANH) may help reduce allogeneic red blood cell transfusion. However, There is a lack of high-quality evidence to support the use of ANH in bone cancer surgery.",[205],"Acute Normovolemic Hemodilution",{"date":113,"type":37},{"date":89,"type":22},{"date":209,"type":22},"2028-05",{"name":43,"class":44},{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":220,"conditions":221,"keywords":223,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":227,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":45},"100643890","glofitamab-combined-with-selinexor-in-patients-with-relapsedrefractory-diffuse-large-b-cell-lymphoma-100643890","NCT07669194","Glofitamab Combined With Selinexor in Patients With Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma","Observational Real-World Study of Glofitamab Combined With Selinexor for Patients With Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma (R\u002FR DLBCL)","Glofit-Sel","Inclusion Criteria:\n\n* Age 18 years and older at the time of informed consent.\n* Histologically confirmed CD20+ diffuse large B-cell lymphoma (DLBCL).\n* Relapsed or refractory disease, having previously received at least two lines of systemic therapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.\n* Presence of measurable disease.\n* Adequate hematologic, hepatic, and renal function.\n* Willingness to use effective contraception methods during the study and for a specified period after the last dose.\n* Willing and able to provide written informed consent and comply with the study protocol.\n\nExclusion Criteria:\n\n* Prior treatment with any CD20\u002FCD3 bispecific antibodies or XPO1 inhibitors.\n* Current or prior history of central nervous system (CNS) involvement by lymphoma or other significant CNS diseases.\n* Active and uncontrolled systemic infections, including known HIV infection, active Hepatitis B virus (HBV), or active Hepatitis C virus (HCV) infection.\n* Active autoimmune diseases requiring systemic immunosuppressive therapy.\n* Clinically significant, severe, or uncontrolled cardiovascular diseases.\n* Other active invasive malignancies within the past 2 years (with exceptions for adequately treated localized cancers).\n* Recent major surgery or receipt of live attenuated vaccines within a specified timeframe prior to the study.\n* Severe gastrointestinal conditions that may significantly affect the absorption of oral medications.\n* Known severe allergic reactions to any of the study drugs or their excipients.\n* Pregnant or breastfeeding women.",{"count":54,"type":22},"Assess the efficacy and safety of glofitamab in combination with selinexor for the treatment of relapsed or refractory diffuse large B-cell lymphoma (R\u002FR DLBCL) in patients who have received at least two prior lines of systemic therapy.",[222],"Diffuse Large B-Cell Lymphoma (DLBCL)",[224,225,226],"Relapsed\u002FRefractory","Glofitamab","Selinexor",{"date":113,"type":37},{"date":229,"type":22},"2026-06-10",{"date":231,"type":22},"2029-04-30",{"name":43,"class":44},{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":23,"phases":242,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":247,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":45},"100644033","phase-2-intensified-adjuvant-therapy-for-high-risk-newly-diagnosed-glioblastoma-with-subtotal-resection-or-short-term-progression-100644033","NCT07670026","Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression","Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression: A Prospective, Single-Arm Phase II Clinical Study","Inclusion Criteria:\n\n* Voluntary participation in the clinical study: fully understands and is informed about the study and has signed the informed consent form in writing; willing to comply with and able to complete all trial procedures.\n* Age: \\>=18 years; male or female.\n* Pathologically confirmed Glioblastoma.\n* Subtotal resection or recurrent\u002Fprogressive disease 4-6 weeks after surgery (before radiotherapy).\n* Adequate organ and bone marrow function, with no severe hematopoietic dysfunction or cardiac, pulmonary, hepatic, renal dysfunction, or immunodeficiency:\n\n  1. Complete blood count: absolute neutrophil count (ANC) \\>=1.5\\*10\\^9\u002FL (1500\u002Fmm3), platelets \\>=75\\*10\\^9\u002FL, hemoglobin \\>=9 g\u002FdL (if there is bone marrow involvement, platelets \\>=50\\*10\\^9\u002FL, ANC \\>=1.0\\*10\\^9\u002FL, hemoglobin \\>=8 g\u002FdL).\n  2. Liver function: serum bilirubin \\\u003C=1.5 times the upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C=1.5 times ULN (if there is liver involvement, AST and ALT \\\u003C=5 times ULN are allowed).\n  3. Renal function: serum creatinine \\\u003C=1.5 times ULN.\n  4. Coagulation function: INR \\\u003C=1.5 times ULN; PT and APTT \\\u003C=1.5 times ULN (unless the subject is receiving anticoagulant therapy and PT and APTT at screening are within the expected range for anticoagulant therapy).\n* Left ventricular ejection fraction (LVEF) \\>=50% on cardiac function examination.\n* Negative serum pregnancy test, and effective contraceptive measures from signing the informed consent form until 6 months after the last chemotherapy.\n* Thyroid-stimulating hormone (TSH), free thyroxine (FT4), or free triiodothyronine (FT3) within the normal range ±10%.\n* Ophthalmologic examination: including dilated fundus examination, slit-lamp examination, and color fundus photography.\n\nExclusion Criteria:\n\n* Currently participating in another clinical study, or less than 4 weeks since completion of treatment in a previous clinical study.\n* History of malignancy other than Glioblastoma within the past 3 years, or another uncured primary malignancy.\n* Prior history of brain radiotherapy.\n* Pregnant or lactating women.\n* Patients assessed as having contraindications to radiotherapy.\n* Severe active comorbidity that would affect the study treatment.\n* Active infection requiring systemic anti-infective treatment, including but not limited to bacterial, fungal, or viral infection.\n* Within 6 months before screening, New York Heart Association (NYHA) class III or IV heart failure, unstable angina, severe poorly controlled ventricular arrhythmia, or electrocardiographic evidence of acute ischemia or myocardial infarction.\n* QTcF interval \\>480 msec, unless secondary to bundle branch block.\n* Uncontrolled concomitant disease, including but not limited to uncontrolled hypertension, active peptic ulcer disease, or hemorrhagic disease.\n* Prior history of mental illness; lack of capacity for civil conduct or limited capacity for civil conduct.\n* Any medical history or disease evidence, treatment, or abnormal laboratory value that may interfere with trial results or prevent the subject from fully participating in the study, or any other condition that the investigator considers unsuitable for enrollment.",{"count":241,"type":22},31,[243],"PHASE2","\\*\\*Brief Summary\\*\\*\n\nThe goal of this clinical trial is to learn whether intensified adjuvant treatment is safe and may help delay disease progression in adults with high-risk newly diagnosed glioblastoma. High-risk newly diagnosed glioblastoma in this study includes glioblastoma that has been partially removed by surgery or glioblastoma that shows early progression or recurrence before postoperative radiotherapy.\n\nThe main questions this study aims to answer are:\n\n* Does intensified adjuvant treatment improve median progression-free survival in participants with high-risk newly diagnosed glioblastoma?\n* How long do participants survive after receiving this treatment?\n* What medical problems do participants have during or after intensified adjuvant treatment?\n* How often do participants develop radiation necrosis?\n* How does this treatment affect participants' quality of life?\n\nParticipants will:\n\n* Receive postoperative concurrent radiotherapy and temozolomide chemotherapy.\n* Receive a higher radiation dose to the residual tumor or early recurrent\u002Fprogressive lesion, while standard radiation doses are given to the tumor bed and surrounding high-risk and low-risk areas.\n* Receive adjuvant temozolomide after concurrent chemoradiotherapy.\n* Receive sintilimab and bevacizumab by intravenous infusion once every 21 days for up to 1 year.\n* Have regular blood tests, biochemical tests, thyroid function tests, myocardial enzyme tests, electrocardiograms, and other safety assessments.\n* Have enhanced brain MRI scans regularly to evaluate disease status.\n* Be followed by clinic visits and\u002For telephone calls to collect information about disease progression, survival, side effects, later cancer treatments, and quality of life.",[246],"Glioblastoma",{"date":113,"type":37},{"date":249,"type":37},"2025-12-01",{"date":251,"type":22},"2027-12-01",{"name":43,"class":44},{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":260,"targetDuration":4,"studyType":23,"phases":262,"briefSummary":263,"conditions":264,"keywords":266,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":269,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":45},"100643885","phase-2-skb264-plus-goleirex-in-advanced-kras-g12c-mutant-nsclc-a-phase-ii-study-100643885","NCT07670013","SKB264 Plus Goleirex in Advanced KRAS G12C-Mutant NSCLC: A Phase II Study","A Multicenter, Single-Arm, Phase II (Simon Two-Stage) Study of Lucankizumab (SKB264) Plus Goleirex (KRAS G12C Inhibitor) as First-Line Treatment for KRAS G12C-Mutated Advanced NSCLC","Inclusion Criteria:\n\n* Voluntarily participate in the study and sign the informed consent form (ICF).\n* Male or female subjects aged ≥18 years and ≤75 years at the time of signing the ICF.\n* Expected survival time of ≥3 months.\n* Histologically or cytologically confirmed non-squamous non-small cell lung cancer (NSCLC) with unresectable locally advanced stage (Stage ⅢB\u002FⅢC), metastatic or recurrent stage (Stage Ⅳ) that is not eligible for radical concurrent chemoradiotherapy, in accordance with the 8th edition of the TNM --Staging System for Lung Cancer by the International Association for the Study of Lung Cancer (IASLC) and the American Joint Committee on Cancer (AJCC).\n\nConfirmed KRAS G12C mutation-positive by a qualified laboratory (CAP\u002FCLIA or nationally accredited) using next-generation sequencing (NGS) or an equivalent method; positivity in either tissue samples or plasma circulating tumor DNA (ctDNA) is acceptable. If plasma testing is negative and tissue testing is feasible, supplementary tissue testing is recommended.\n\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 to 1.\n* Definition for first-line systemic therapy of advanced disease: No prior systemic anti-tumor therapy for metastatic\u002Fadvanced disease. For subjects who previously received radical post-surgical therapy, chemoradiotherapy or immunotherapy alone, enrollment is permitted only if the interval from the last dose to disease recurrence is ≥6 months.\n* Presence of at least one measurable lesion in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1; measurable lesions within a prior radiotherapy field or after local treatment may be selected as target lesions if disease progression is documented.\n* Sufficient organ and bone marrow function, including the following:\n\nAdequate hematopoietic function: Absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL, platelet count ≥100×10⁹\u002FL, hemoglobin ≥9 g\u002FdL. No blood transfusion or treatment with granulocyte colony-stimulating factor (G-CSF), thrombopoietin (TPO), erythropoietin (EPO) or other similar agents is allowed within 14 days prior to blood routine testing.\n\n* Adequate liver function: Total bilirubin (TBIL) \\\u003C1.5×upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C2.5×ULN; for subjects with Gilbert's syndrome, TBIL \\\u003C2×ULN is acceptable; for subjects with liver metastases from tumor, AST and ALT \\\u003C5.0×ULN is required; for subjects with extrahepatic obstruction confirmed by direct bilirubin (DBIL) testing, TBIL \\\u003C3.0×ULN is permitted.\n* Adequate renal function: Serum creatinine (Cr) ≤1.5×ULN, or if Cr \\>1.5×ULN, creatinine clearance (CrCl) ≥60 mL\u002Fmin calculated by the Cockcroft-Gault formula.\n* Adequate coagulation function: Prothrombin time (PT)\u002Factivated partial thromboplastin time (APTT) \\\u003C1.5×ULN, and international normalized ratio (INR) \\\u003C1.5 or within the target range for anticoagulant therapy.\n\nSerum magnesium level within the normal range.\n\n* Toxic effects from prior anti-tumor therapy must have recovered to baseline levels (excluding residual alopecia) or grade ≤1 at enrollment (grade ≤2 neurotoxicity is acceptable). For immune-related adverse events (irAEs) involving the endocrine system caused by prior immunotherapy (e.g., immune-related hypothyroidism), subjects with well-controlled symptoms under stable-dose hormone replacement therapy or physiological-dose corticosteroid therapy may be enrolled if the investigator assesses that the treatment does not interfere with the administration of study drugs and safety evaluation.\n* Female subjects of childbearing potential and male subjects whose partners are of childbearing potential must adopt effective contraceptive measures from the time of signing the ICF until 6 months after the last dose of study drug. Female subjects of childbearing potential must have a negative blood pregnancy test result within 7 days (inclusive) prior to the first dose of study drug. If a urine pregnancy test result is inconclusive, a blood pregnancy test is required.\n* The investigator judges that the subject is capable of effective communication, complying with scheduled follow-up visits and completing the study in accordance with the protocol requirements.\n\nExclusion Criteria:\n\n* Prior treatment with a KRAS G12C inhibitor or TROP2-ADC; any prior systemic anti-tumor therapy (chemotherapy, immunotherapy, targeted therapy, etc.) for advanced non-small cell lung cancer (NSCLC).\n* Positive for other clinically approved first-line targetable oncogenic drivers: classic sensitizing EGFR mutations (19del\u002FL858R), ALK\u002FROS1\u002FRET\u002FNTRK fusions, BRAF V600E mutation, MET exon 14 skipping mutation, and other mutations for which guideline-recommended approved first-line targeted therapies are available (to avoid conflict with current standard of care); concurrent mutations such as KRAS combined with STK11\u002FKEAP1 are not exclusion criteria.\n* Histologically or cytologically confirmed mixed NSCLC with small cell carcinoma components or predominantly squamous cell carcinoma components.\n* Significant cardiovascular and cerebrovascular diseases, including:\n\nA confirmed major cardiovascular adverse event within 6 months, such as myocardial infarction, angina pectoris, heart failure, severe arrhythmia, or receipt of angioplasty, vascular stenting, coronary artery bypass grafting, or other similar procedures; -Clinically significant prolonged QT\u002FQTcF interval on electrocardiogram (QTcF \\>470 ms in females or QTcF \\>450 ms in males); A confirmed major cerebrovascular adverse event within 3 months, such as intracerebral hemorrhage or cerebral infarction.\n\nUncontrolled central nervous system (CNS) disease: active CNS metastases requiring urgent local therapy; meningeal carcinomatosis.\n\n-Interstitial lung disease (ILD)\u002Fdrug-induced pneumonitis: active ILD\u002Fpneumonitis or a history of ILD\u002Fpneumonitis requiring systemic corticosteroid therapy; baseline chest imaging showing active ILD-like changes.",{"count":261,"type":22},43,[243],"This is a multicenter, single-arm, phase II (Simon two-stage) prospective interventional clinical study. The primary objective is to evaluate the efficacy and safety of lucankizumab (SKB264) in combination with golelixir (a KRAS G12C inhibitor) as first-line treatment in patients with KRAS G12C-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). Specifically, the primary endpoint is the objective response rate (ORR) assessed by investigators per RECIST 1.1 to verify the core antitumor activity of the combination regimen. Secondary objectives include comprehensive evaluation of overall efficacy via disease control rate (DCR), duration of response (DoR), time to response (TTR), progression-free survival (PFS), and overall survival (OS). Safety will be monitored in accordance with NCI CTCAE 5.0, including the incidence and severity of adverse events (AEs) and serious adverse events (SAEs), to characterize the safety profile of the combination and the feasibility of dose modifications. This study aims to provide scientific evidence for the use of this combination regimen as first-line therapy for KRAS G12C-mutated advanced NSCLC and to explore a more optimal treatment option for this patient population.",[265],"NSCLC",[267,268],"SBK264","Goleirex",{"date":113,"type":37},{"date":271,"type":37},"2026-04-01",{"date":273,"type":22},"2028-06",{"name":43,"class":44},{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":23,"phases":285,"briefSummary":286,"conditions":287,"keywords":292,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":298,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":21},"100597672","phase-2-sintilimab-combined-with-tafolecimab-and-chemotherapy-as-first-line-treatment-for-extensive-stage-small-cell-lung-cancer-100597672","NCT07061535","Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer","Efficacy and Safety of Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (STAR-SCLC)：A Prospective, Single Arm Trial","STAR-SCLC","Key Inclusion Criteria:\n\n* Age ≥18 years, ECOG performance status 0-1;\n* Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC) according to Veterans Administration Lung Study Group criteria;\n* Previously not receiving systemic treatment for ES-SCLC;\n* Greater than or equal to 1 measurable lesion exists according to RECIST v1.1;\n* Expected survival \\>= 12 weeks;\n* Adequate organ system functions (no blood transfusion or component blood use within 14 days before testing).\n\nKey Exclusion Criteria:\n\n* Previously receiving systemic anti-tumor therapy for ES-SCLC;\n* Combined SCLC (mixed SCLC and NSCLC histological types) or transformed SCLC confirmed by histological or cytological examination;\n* Receiving other investigational drugs or participated in other interventional clinical studies within 4 weeks before signing the informed consent form;\n* Receiving systemic immunostimulant treatment within 4 weeks before enrollment;\n* Active central nervous system (CNS) metastases (asymptomatic patients with stable lesions allowed);\n* Severe cardiovascular disease;\n* Severe chronic\u002Factive infections requiring systemic antibacterial, antifungal or antiviral treatment within 2 weeks before enrollment;\n* Active hepatitis B virus (HBV)\u002F hepatitis C virus (HCV)\u002F human immunodeficiency virus (HIV) infection;\n* Active autoimmune diseases, a history of interstitial lung disease, or other uncontrolled systemic diseases;\n* Pregnancy or lactation;\n* Having a disease that requires systemic corticosteroids or other immunosuppressants to be treated within ≤14 days before enrollment;\n* Requiring at least monthly or more frequent drainage of pleural and\u002For pericardial or peritoneal effusion;\n* Using attenuated live vaccines, or planned to receive attenuated live vaccines within 28 days before enrollment;\n* Known to be allergic to Sintilimab or Tafolecimab or its excipients, having a history of severe allergic reaction to any monoclonal antibody, or having a history of allergy to cisplatin, carboplatin or etoposide;\n* Toxicity caused by previous anti-cancer treatment has not recovered to baseline or stable state at the time of enrollment;\n* Creatinine clearance rate \\\u003C 60 mL\u002Fmin (cisplatin) or \\\u003C 45 mL\u002Fmin (carboplatin)\n* Uncontrolled or symptomatic hypercalcemia.",{"count":284,"type":22},40,[243],"This is a single arm, multi-center clinical trial. The goal of this clinical trial is to evaluate the efficacy, safety and biomarkers of Tafolecimab combined with Sintilimab and Chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC). Tafolecimab is a recombinant fully humanized monoclonal antibody against proprotein convertase subtilisin\u002Fkexin type 9 (PCSK-9), which can reduce low-density lipoprotein-C levels and increase the expression level of major histocompatibility complex class I (MHC-I) on tumor cells. Sintilimab is a fully humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1).",[288,289,290,291],"Extensive-stage Small Cell Lung Cancer (ES-SCLC)","Extensive Stage Lung Small Cell Cancer","Extensive-Stage Small-Cell Lung Cancer","Extensive Disease Small Cell Lung Cancer",[293,294,295,296,297],"Tafolecimab","Sintilimab","immunotherapy","PCSK9 inhibitor","SCLC",{"date":134,"type":37},{"date":300,"type":37},"2025-07-30",{"date":302,"type":22},"2027-08-01",{"name":43,"class":44},{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":311,"targetDuration":4,"studyType":23,"phases":313,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":319,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":323,"locationsCount":45},"100551365","the-effect-of-acute-normovolemic-hemodilution-in-bone-tumor-surgery-100551365","NCT06459141","The Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery","The Effect of Acute Normovolemic Hemodilution on Intraoperative Allogeneic Transfusion in Bone Tumor Surgery: a Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n1. age 18 to 75 years;\n2. undergoing elective bone tumor resection surgery;\n3. preoperative hemoglobin ≥11 g\u002FdL;\n\nExclusion Criteria:\n\n1. using a tourniquet;\n2. palliative operation or minimally invasive surgery;\n3. BMI\\\u003C18.5 or \\>30Kg\u002Fm\\^2;\n4. international normalized ratio (INR) \\>1.5 or platelet count \\\u003C100 × 10\\^9\u002FL;\n5. cardiopulmonary insufficiency;\n6. hepatic and renal dysfunction;\n7. active infectious disease;\n8. allergy to succinyl gelatin;\n9. pregnancy;\n10. declined participation in the study or declined blood transfusion",{"count":312,"type":22},150,[104],"The prevention of intraoperative allogenetic blood transfusion has the potential to reduce complications, hospital stays, and long-term prognosis in patients undergoing bone cancer surgery. Data from previous studies suggest that the clinical efficacy of acute normovolemic hemodilution (ANH) has always been controversial. The HEAL trial will assess whether ANH will reduce the volume of intraoperative allogeneic red blood cell transfusion in patients undergoing bone cancer surgery.",[205,316,317,318],"Bone Tumor","Goal-Directed Fluid Therapy","Transfusion",{"date":113,"type":37},{"date":321,"type":37},"2024-06-07",{"date":209,"type":22},{"name":43,"class":44},{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":17,"minAge":331,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":23,"phases":334,"briefSummary":335,"conditions":336,"keywords":338,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":344,"completionDateStruct":345,"leadSponsor":347,"locationsCount":348},"100644156","study-on-the-impact-of-decolonization-treatment-of-pneumocystis-jirovecii-on-the-frequency-of-acute-exacerbation-in-copd-100644156","NCT07665359","Study on the Impact of Decolonization Treatment of Pneumocystis Jirovecii on the Frequency of Acute Exacerbation in COPD","A Multicenter, Prospective, Double-blind, Randomized Controlled Study on the Impact of Decolonization Treatment on the Frequency of Acute Exacerbation in Patients With Chronic Obstructive Pulmonary Disease Colonized With Pneumocystis Jirovecii","Inclusion Criteria:\n\n* Age 40 and above，male or female；\n* COPD who meet the diagnostic criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2026 ( post-bronchodilator FEV1\u002Fforced vital capacity \\[FVC\\] ratio \\\u003C 0.7 and post-bronchodilator FEV1% predicted ≥ 30%), and have documented history of high exacerbation risk (Group E, defined as exacerbation history of ≥ 1 moderate or severe acute exacerbation within 12 months prior to inclusion)；\n* Background triple therapy (ICS + LABA + LAMA) for 3 months prior to randomization with a stable dose of medication for ≥1 month prior to inclusion; Double therapy (LABA + LAMA) allowed if ICS is contraindicated；\n* PCR detection of Pneumocystis jirovecii in induced sputum is positive；\n* Informed consent\n\nExclusion Criteria:\n\n* Allergic to TMP, SMX or sulfonamide drugs；\n* There are pneumonia or other infections that require long-term use of antibacterial drugs (such as tuberculosis, NTM, other fungi, etc.)；\n* Having used antibiotics within the previous 4 weeks prior to screening；\n* Experience of AECOPD events within the previous 4 weeks prior to screening;\n* Having a definite immunodeficiency disorder or receiving immunosuppressive therapy (such as HIV, agranulocytosis, solid organ or hematopoietic stem cell transplantation, malignant tumors, using long-term high-dose hormones \\> 20mg\u002Fday prednisone equivalent for more than 4 weeks)；\n* Severe liver and kidney dysfunction (ALT\u002FAST \\> 3 times the upper limit of normal value, eGFR \\\u003C 60 mL\u002Fmin\u002F1.73m²)；\n* Pregnant, lactating women or those planning to become pregnant;\n* Folic acid deficiency-induced microcytic anemia;\n* Currently using coumarin, phenytoin, pioglitazone, repaglinide, rosiglitazone, glipizide or glibenclamide;\n* Currently participating in other interventional clinical studies；","40 Years",{"count":333,"type":22},630,[104],"Previous researches have found the common colonization of Pneumocystis jirovecii (Pj) in the airways of people with chronic obstructive pulmonary disease (COPD). And this colonization may exacerbate airway inflammation and increase the frequency of acute exacerbation in people with COPD.\n\nThe goal of this clinical trial is to study if \"decolonization treatment\" (that is, removing these colonizing Pj) works to improve the prognosis of COPD colonized by Pj in adults. The main question it aims to answer is:\n\n* Does the Trimethoprim-Sulfamethoxazole (TMP-SMX, an antibiotics) decolonization treatment reduce the frequency of acute exacerbation in participants with COPD colonized by Pj who have a high risk of acute exacerbation.\n\nResearchers will compare TMP-SMX to a placebo (a look-alike substance that contains no drug) to see if TMP-SMX works to reduce the frequency of acute exacerbation of COPD.\n\nParticipants will:\n\n* Take drug TMP-SMX or a placebo 2 tablet every day for 4 weeks.\n* Visit the clinic after 2 weeks, 1 month, 3 months, 6 months and 12 months for survey questions, checkups and tests.\n* Keep a diary of their symptoms and the number of times they experience acute exacerbations",[337],"Chronic Obstructive Pulmonary Disease (COPD)",[339,340,341],"Chronic Obstructive Pulmonary Disease","Pneumocystis jirovecii","Trimethoprim-Sulfamethoxazole","2026-06-18",{"date":85,"type":37},{"date":34,"type":22},{"date":346,"type":22},"2029-05-01",{"name":43,"class":44},20,{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":355,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":357,"targetDuration":359,"studyType":80,"phases":4,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":45},"100641396","assessment-of-ct-ffr-in-patients-with-ccs-a-prospective-multicenter-cohort-study-100641396","NCT07659119","Assessment of CT-FFR in Patients With CCS: A Prospective Multicenter Cohort Study","Assessment of Coronary Computed Tomography-Derived Fractional Flow Reserve in Patients With Chronic Coronary Syndrome: A Prospective Multicenter Cohort Study","ACCURATE-PRO","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Clinical diagnosis of chronic coronary syndrome (CCS).\n* Completed coronary computed tomography angiography (CCTA) examination and successfully obtained CT-derived fractional flow reserve (CT-FFR) results.\n* The subject or their legal representative voluntarily participates in this study and has signed the written informed consent form.\n\nExclusion Criteria:\n\n* Acute coronary syndrome (ACS), including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), or acute episodes of unstable angina.\n* Unable to obtain valid CT-FFR results, or the image quality is insufficient to support analysis.\n* Pregnant patients or those who intend to become pregnant during the study period.\n* Non-cardiac comorbidities indicating a life expectancy of less than one year.\n* Failure to sign the informed consent form.\n* Inability to complete the follow-up or explicit refusal to participate in the follow-up.\n* Patients with cognitive impairment or psychiatric disorders confirmed by clinical diagnosis or investigator assessment.\n* Patients who are illiterate or semi-literate, or who, due to any visual impairment or reading\u002Fwriting disability, are unable to independently read the subject information sheet without assistance and are unable to personally provide written informed consent.\n* Any other conditions deemed unsuitable for participation in this study by the investigators",{"count":358,"type":22},3000,"5 Years","The ACCURATE-PRO study is an investigator-initiated, prospective, multicenter, observational, real-world cohort study. The core objective in managing chronic coronary syndrome (CCS) is to identify clinically significant myocardial ischemia to guide treatment decisions and improve long-term prognosis. While coronary computed tomography angiography (CCTA) is a crucial non-invasive anatomical imaging tool, it has limitations in determining the functional significance of coronary stenosis. Computed tomography-derived fractional flow reserve (CT-FFR) provides this functional assessment non-invasively based on CCTA images. However, there is a lack of systematic, prospective, multicenter evidence regarding its clinical value in risk stratification, treatment decision support, and prognostic evaluation for a continuous, real-world spectrum of CCS patients in China.\n\nThis study aims to evaluate the relationship between abnormal CT-FFR results and the risk of 1-year major adverse clinical events in CCS patients undergoing CCTA and CT-FFR. The study hypothesizes that abnormal CT-FFR is associated with a higher risk of 12-month major adverse clinical events, and that CT-FFR results are significantly correlated with subsequent treatment strategies, providing important value in risk stratification and mid-to-long-term prognosis.\n\nThe trial plans to consecutively enroll approximately 3,000 patients across multiple clinical centers in China. Eligible participants must be 18 years or older, have a clinical diagnosis of CCS, and have successfully obtained CT-FFR results following a CCTA examination. Patients will be excluded if they have acute coronary syndrome (such as STEMI, NSTEMI, or acute unstable angina), unanalyzable CT-FFR results\u002Fimage quality, or non-cardiac conditions limiting their life expectancy to less than one year.\n\nSince this is an observational study, it will not alter routine clinical care pathways or assign interventions. The primary exposure factor analyzed will be the lowest CT-FFR result per patient, comparing an abnormal CT-FFR group (≤ 0.80) to a normal CT-FFR group (\\> 0.80).\n\nParticipants will be followed up via telephone, outpatient visits, or hospitalization at 6, 12, 24, and 60 months after enrollment. The primary endpoint is a composite of all-cause death, myocardial infarction (MI), or ischemia-driven revascularization within 1 year after enrollment. Key secondary endpoints include the occurrence of the primary endpoint at 24 and 60 months, target vessel failure (a composite of cardiac death, target vessel MI, or target vessel revascularization), stroke, health economics analysis, and the association between CT plaque characteristics and clinical outcomes.",[184],"2026-06-16",{"date":187,"type":37},{"date":365,"type":37},"2024-05-01",{"date":367,"type":22},"2034-05-31",{"name":43,"class":44},{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":375,"enrollmentInfo":376,"targetDuration":4,"studyType":23,"phases":378,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":384,"completionDateStruct":385,"leadSponsor":387,"locationsCount":4},"100641894","study-of-teprenone-in-the-treatment-of-glucocorticoid-induced-drug-related-gastrointestinal-injury-100641894","NCT07654049","Study of Teprenone in the Treatment of Glucocorticoid-Induced Drug-Related Gastrointestinal Injury","Inclusion Criteria:\n\n1. Age 18 to 70 years;\n2. Patients diagnosed with systemic lupus erythematosus (SLE) meeting the 2019 EULAR\u002FACR classification criteria for SLE;\n3. Receiving moderate to high doses of glucocorticoids (prednisone or its equivalent 30-60 mg , once daily);\n4. Voluntarily participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Presence of other gastric mucosal lesions, such as active ulcers, active bleeding, gastric cancer, gastric polyps, etc.;\n2. History of subtotal gastrectomy;\n3. History of endoscopic treatments, such as Endoscopic Submucosal Dissection (ESD) or Endoscopic Mucosal Resection (EMR);\n4. Significant psychiatric and behavioral abnormalities or mood disorders;\n5. History of clinically significant diseases, including: Chronic congestive heart failure (NYHA Class IV); History of echocardiography-confirmed ejection fraction (EF) \\\u003C 30%; Myocardial infarction, acute coronary syndrome, viral myocarditis, or pulmonary embolism within 6 months; Coronary revascularization within 6 months; Severe arrhythmia requiring treatment with Class Ia or III antiarrhythmic drugs;History of sick sinus syndrome, Mobitz II and Complete Heart Block without a permanent pacemaker implanted; QTc interval≥480 ms on screening ECG;\n6. Laboratory abnormalities at screening as follows: Total bilirubin \\> 3 times ULN (Upper Limit of Normal); AST\u002FALT \\> 3 times ULN; Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73m²;\n7. Currently receiving treatment (e.g., chemotherapy, radiotherapy, immunotherapy) for other malignancies;\n8. Pregnant or lactating women;\n9. Allergy or hypersensitivity to the study drug(s).","70 Years",{"count":377,"type":22},100,[104],"Objective:\n\nTo evaluate the efficacy, safety, and adherence of the gastric mucosal protective agent teprenone in the treatment of glucocorticoid-induced drug-related gastrointestinal injury.\n\nStudy Design:\n\nThis study is a prospective, open-label, randomized controlled trial. The study population consists of patients with systemic lupus erythematosus requiring medium- to high-dose glucocorticoid therapy (30-60 mg\u002Fday). Eligible patients are enrolled according to inclusion and exclusion criteria and randomly assigned in a 1:1 ratio into two groups: a proton pump inhibitor (PPI) group and a mucosal protective agent group. The PPI group receives omeprazole capsules 20 mg once daily before meals, while the mucosal protective agent group receives teprenone 50 mg three times daily after meals. Both groups are treated for 12 weeks.\n\nPrimary Endpoint:\n\nTo assess the improvement in the 7-point overall symptom scale from baseline to week 12.",[381],"Gastrointestinal and Digestive Disorder","2026-06-15",{"date":137,"type":37},{"date":155,"type":22},{"date":386,"type":22},"2027-06-01",{"name":43,"class":44},{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":17,"minAge":394,"maxAge":395,"enrollmentInfo":396,"targetDuration":4,"studyType":23,"phases":398,"briefSummary":399,"conditions":400,"keywords":403,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":412,"leadSponsor":413,"locationsCount":4},"100643616","a-comparative-study-of-the-efficacy-of-myopia-control-lenses-with-different-mechanisms-on-controlling-myopia-progression-in-patients-with-intermittent-exotropia-100643616","NCT07642934","A Comparative Study of the Efficacy of Myopia Control Lenses With Different Mechanisms on Controlling Myopia Progression in Patients With Intermittent Exotropia","Inclusion Criteria:\n\n1. Participants aged 6 to 12 years (6 ≤ age ≤ 12 years). Written informed consent from legal guardians is mandatory.\n2. Patients with basic-type intermittent exotropia (IXT) meeting all the following criteria:\n\n   1. Intermittent or constant exotropia at the distance of 6 meters, and intermittent exotropia or esophoria at the near distance of 33 centimeters;\n   2. Distance exodeviation ≥ 10 prism diopters (PD) measured via the prism and alternate cover test (PACT);\n   3. The difference between near and distance deviation ≤ 10 PD.\n3. Based on cycloplegic spherical equivalent (SE), the myopic refractive error of both eyes ranges from -6.0 D to -0.5 D.\n4. The logMAR value of monocular distance best-corrected visual acuity (BCVA) measured by the ETDRS chart is ≤ 0.2, and no amblyopia is present.\n5. Parents and children are willing to participate in this clinical trial and can complete the entire study protocol.\n6. Children have healthy eyes without organic ocular diseases.\n\nExclusion Criteria:\n\n1. Participants who have worn myopia control glasses or received other myopia interventions, including low-concentration atropine and phototherapy instruments, within the past 6 months (excluding DIMS and DOT glasses).\n2. Those with severe systemic diseases or cognitive impairment that hinders follow-up attendance and clinical examinations.\n\n4\\. Subjects with astigmatism of ≥ 2 diopters (D) in either eye after cycloplegia; individuals enrolled in other interventional trials.\n\n5\\. Patients with active ocular inflammation in either eye. 6. Those diagnosed with ocular diseases or presenting with clinically significant abnormalities on ophthalmic examinations.\n\n7\\. Participants are currently receiving visual function training or other clinical interventions for intermittent exotropia.\n\n8\\. Individuals who decline to complete the 1-year follow-up period.","6 Years","12 Years",{"count":397,"type":22},120,[104],"The goal of this clinical trial is to compare the efficacy of myopia control lenses with different working principles in patients with intermittent exotropia aged 6 to 12 years. The main questions it aims to answer are:\n\nAre there any differences in the clinical outcomes of DIMS and DOT glasses between children with intermittent exotropia and those with simple myopia (without intermittent exotropia)? Do DIMS and DOT glasses differ in their myopia control efficacy among children with intermittent exotropia? Does wearing DIMS or DOT glasses affect the binocular visual function of children with intermittent exotropia?",[401,402],"Intermittent Exotropia","Myopia",[404,405,406,407],"Intermittent exotropia","Myopia control","DIMS","DOT","2026-06-09",{"date":410,"type":37},"2026-06-11",{"date":155,"type":22},{"date":157,"type":22},{"name":43,"class":44},{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":420,"targetDuration":4,"studyType":23,"phases":422,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":432,"leadSponsor":434,"locationsCount":45},"100643213","phase-4-the-effect-of-bupivacaine-liposomes-on-postoperative-pain-in-lung-transplant-patients-after-intercostal-nerve-block-a-randomized-controlled-study-100643213","NCT07641647","The Effect of Bupivacaine Liposomes on Postoperative Pain in Lung Transplant Patients After Intercostal Nerve Block: a Randomized Controlled Study","Inclusion Criteria:\n\n* Patients with end-stage lung disease undergoing bilateral lung transplantation; Age \\>18 years; Expected discontinuation of mechanical ventilation within 48 hours after surgery; The patient or legally authorized representative signs the informed consent form and agrees to participate in the study and follow-up.\n\nExclusion Criteria:\n\n* Body mass index ≤18 kg\u002Fm² or ≥35 kg\u002Fm²; Allergy or contraindication to local anesthetics; Preoperative tracheal intubation or requirement for extracorporeal life support; Expected use of other types of nerve block; Active systemic infection or infection at the planned block site; Severe hepatic insufficiency; Severe renal impairment; Chronic pain, neuropathic pain, long-term use of analgesics, or use of other psychotropic medications; Preoperative cognitive impairment, cerebrovascular disease, or history of psychiatric disorders; Severe coagulation dysfunction; Concomitant surgery during the same operative session; Pregnant or breastfeeding women.",{"count":421,"type":22},88,[423],"PHASE4","The goal of this clinical trial is to evaluate the efficacy and safety of liposomal bupivacaine for postoperative analgesia in adult patients undergoing lung transplantation. The main questions it aims to answer are:\n\nDoes liposomal bupivacaine reduce postoperative opioid consumption after lung transplantation? Does liposomal bupivacaine relieve postoperative pain without increasing adverse events?\n\nResearchers will compare patients receiving liposomal bupivacaine combined with bupivacaine hydrochloride with patients receiving bupivacaine hydrochloride alone to see whether liposomal bupivacaine provides better postoperative analgesia and reduces opioid requirements after lung transplantation.\n\nParticipants will:\n\nReceive lung transplantation under standard perioperative care. Receive intercostal nerve block with either liposomal bupivacaine combined with bupivacaine hydrochloride or bupivacaine hydrochloride alone.\n\nBe assessed for postoperative opioid consumption, pain scores, recovery-related outcomes, and adverse events after surgery.",[426,427,428],"Lung Transplantation","Pain Management","Liposomal Bupivacaine","2026-06-07",{"date":410,"type":37},{"date":34,"type":22},{"date":433,"type":22},"2028-07-01",{"name":43,"class":44},{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":441,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":443,"conditions":444,"keywords":451,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":453,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":45},"100625066","construction-and-clinical-validation-of-a-predictive-model-for-postoperative-adjuvant-therapy-in-hepatocellular-carcinoma-based-on-whole-slide-digital-pathological-images-and-deep-learning-100625066","NCT07417800","Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning","Inclusion Criteria:\n\n* Histopathologically confirmed hepatocellular carcinoma;\n* Aged more than 18 years;\n* Underwent radical resection of primary liver cancer (R0 resection);\n* Availability of postoperative H\\&E-stained paraffin embedded tissue sections suitable for digital whole-slide imaging;\n* Had complete and accessible clinicopathological data and follow-up data;\n* Has complete and evaluable preoperative and postoperative contrast-enhanced CT or MRI imaging with standardized scanning parameters and no severe artifacts, meeting the quality requirements for radiomic and artificial intelligence analysis.\n\nExclusion Criteria:\n\n* Significant missing clinical or follow-up data;\n* Concurrent primary malignancy in other organs;\n* Positive surgical margin (R1 or R2 resection);\n* Tissue sections of poor quality (e.g., severe fading, folding, damage) unsuitable for digital scanning or analysis;",{"count":442,"type":22},11000,"Hepatocellular carcinoma (HCC) is a high-mortality global malignancy with a heavy disease burden in China. Although curative surgical resection improves survival for early-stage HCC patients, the 5-year postoperative recurrence rate remains as high as 50%-70%. Postoperative adjuvant TACE and systemic TKIs are standard treatments for high-risk HCC, yet both therapies have prominent drawbacks, including limited response rates, unavoidable toxicities, and inconsistent clinical benefits. Current treatment decisions rely on conventional clinical and pathological features without precise biomarkers, leading to inadequate individualized therapy and wasted medical resources.\n\nTumor immune microenvironment and multimodal imaging-pathological features critically determine HCC treatment sensitivity. Artificial intelligence and deep learning based on preoperative radiomics and postoperative H\\&E whole-slide imaging (WSI) can capture hidden tumor biological characteristics and predict therapeutic responses. However, no validated multimodal AI model is available for predicting postoperative TACE and TKI treatment outcomes in HCC, lacking large-scale multicenter prospective evidence.\n\nThis study aims to construct and validate a multimodal deep learning model integrating preoperative contrast-enhanced CT\u002FMRI, postoperative WSI, pathological reports, and clinical data, to precisely identify HCC patients sensitive to postoperative adjuvant TACE or TKI therapy and optimize individualized treatment strategies.\n\nThis is a hybrid retrospective-training and prospective observational multicenter study with no clinical intervention. A total of 10,000 retrospective HCC surgical patients will be enrolled to develop an AI classification model for predicting responses to four postoperative treatment strategies: surgery alone, surgery plus TACE, surgery plus TACE combined with systemic therapy, and surgery plus exclusive systemic therapy. Subsequently, 1,000 eligible postoperative HCC patients will be prospectively and consecutively enrolled from 10-15 centers. The AI model will generate adjuvant therapy predictions without interfering with real clinical decisions. Patients will be divided into prediction-consistent and prediction-inconsistent cohorts based on the match between model predictions and actual treatments. Long-term follow-up will be performed to compare prognostic outcomes and validate the model's real-world performance and stability.\n\nKey inclusion criteria: histopathologically confirmed HCC; aged 18-75 years; received R0 curative resection; available qualified H\\&E-stained FFPE slides for digital scanning; complete clinical, pathological and follow-up data; high-quality preoperative contrast-enhanced CT\u002FMRI images eligible for AI analysis. Key exclusion criteria: prior preoperative anti-tumor therapy with unavailable baseline data; concurrent other primary malignancies; non-R0 resection; unqualified pathological slides or imaging data; severe missing clinical or follow-up information.",[445,446,447,448,449,450],"Hepatocellular Carcinoma (HCC)","Artificial Intelligent","Adjuvant Chemoradiotherapy","TACE","Lenvatinib","Liver Surgery",[445,446,448,452,447],"lenvatinib",{"date":229,"type":37},{"date":455,"type":37},"2025-11-01",{"date":457,"type":22},"2029-12-01",{"name":43,"class":44},{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":100,"enrollmentInfo":465,"targetDuration":4,"studyType":23,"phases":466,"briefSummary":467,"conditions":468,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":4},"100583944","phase-1-efficacy-and-safety-of-trifluridinetipiracil-tas-102-combined-with-bevacizumab-and-serplulimab-in-patients-with-metastatic-colorectal-cancer-undergoing-cytoreductive-surgery-a-single-arm-single-center-clinical-study-100583944","NCT06882915","Efficacy and Safety of Trifluridine\u002FTipiracil (TAS-102) Combined With Bevacizumab and Serplulimab in Patients With Metastatic Colorectal Cancer Undergoing Cytoreductive Surgery: A Single-Arm, Single-Center Clinical Study","Inclusion Criteria:\n\n1. Patients who had undergone cytoreductive surgery (CC0-1) for colorectal cancer with peritoneal metastases;\n2. Patients with extra-peritoneal metastatic lesions that were unlikely to affect prognosis in the short term;\n3. Patients who had failed standard therapies (disease progression or intolerance to oxaliplatin, irinotecan, fluorouracil, or other chemotherapeutic agents) or for whom no effective treatment options were available;\n4. Patients with histologically and radiologically confirmed peritoneal metastasis from colorectal cancer, with microsatellite stable (MSS) status as determined by genetic testing;\n5. Age ≥ 18 years at the time of informed consent;\n6. Estimated life expectancy \\> 6 months;\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n8. Adequate function of major organs (cardiac, hepatic, and renal);\n9. Adequate hematological parameters: absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL, white blood cell count (WBC) ≥ 3.0 × 10⁹\u002FL, hemoglobin ≥ 10 g\u002FdL, and platelet count ≥ 100 × 10⁹\u002FL;\n10. Adequate biochemical parameters: total bilirubin ≤ 1.5 × upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; serum creatinine and blood urea nitrogen (BUN) ≤ 1.5 × ULN;\n11. Ability to comply with the study protocol and follow-up procedures.\n\nExclusion Criteria:\n\n1. Refusal to provide informed consent;\n2. Currently participating in an interventional clinical study, or having received other investigational drugs or devices within 4 weeks prior to enrollment;\n3. Concurrent malignancy, except for malignancies that have been clinically cured;\n4. Other severe diseases that, in the investigator's judgment, may affect follow-up compliance or short-term survival;\n5. Known hypersensitivity to any component of TAS-102, bevacizumab, or serplulimab;\n6. Uncontrolled brain metastases;\n7. Active autoimmune disease;\n8. Pregnant or lactating women;\n9. History of psychiatric disorders;\n10. Uncontrolled comorbidities including, but not limited to, active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, severe coronary artery disease, or cerebrovascular disease, or any other condition deemed by the investigator to render the patient ineligible for enrollment;\n11. Any other condition that the investigator considers unsuitable for enrollment.",{"count":348,"type":22},[25],"Colorectal cancer (CRC) is one of the most common malignant tumors. With the rapid development of China's economy, people's living standards have been significantly improved, and lifestyles and dietary structures have changed. Smoking, drinking, high-fat, high-energy diets, etc. have led to an increase in the incidence of colorectal cancer year by year. Data show that in 2022, there will be 510,000 new cases of colorectal cancer in China, and about 240,000 deaths related to colorectal cancer. Radical surgery is the main initial treatment for early and middle-stage colorectal cancer and some metastatic colorectal cancer. Although the level of surgical treatment of colorectal cancer has been greatly improved and can achieve cure for some patients, its 5-year overall survival rate is only about 60%, and the main cause of death is distant metastasis and recurrence. In recent years, with the in-depth understanding of the treatment mechanism of metastatic colorectal cancer (mCRC), a variety of new treatment options have been proposed and applied in clinical practice in order to improve the quality of life of patients and prolong their survival.\n\nTrifluridine\u002Ftipivirine (TAS-102) is a new type of cytotoxic drug that exerts anti-tumor effects by directly incorporating into DNA chains to destroy DNA function. Its mechanism of action is different from that of fluorouracil drugs, and it can resist 5-fluorouracil (5-FU) resistance, providing a new treatment option for mCRC patients. TAS-102 has been approved in China for mCRC patients who have previously received fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy, as well as those who have previously received or are not suitable for anti-vascular endothelial growth factor (VEGF) therapy and anti-epidermal growth factor receptor (EGFR) therapy (RAS wild type). Bevacizumab, as a monoclonal antibody targeting VEGF, exerts its anti-tumor effect by inhibiting tumor angiogenesis. Putlimumab, as an immune checkpoint inhibitor, enhances the body's immune response to tumors by blocking the PD-1\u002FPD-L1 signaling pathway.\n\nCombination therapy has attracted much attention due to its possible synergistic effect. Studies have shown that TAS-102 combined with bevacizumab can achieve longer overall survival (OS) than TAS-102 monotherapy. In addition, TAS-102 combined with bevacizumab for refractory mCRC has also been approved by the FDA, showing its potential and importance in the treatment of mCRC. Therefore, this study aims to explore the efficacy and safety of TAS-102 combined with bevacizumab and putelimab in patients with mCRC after cytoreductive surgery, in order to provide a more effective treatment for mCRC patients. Through the design of a single-arm, single-center clinical study, we can have a deeper understanding of the efficacy and safety of this combined treatment in a specific patient population, providing a scientific basis for future clinical applications.",[469],"Colorectal Cancer (CRC)","2026-06-04",{"date":472,"type":37},"2026-06-08",{"date":474,"type":22},"2026-06-06",{"date":476,"type":22},"2027-05-01",{"name":43,"class":44},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":12,"sex":484,"minAge":18,"maxAge":375,"enrollmentInfo":485,"targetDuration":4,"studyType":23,"phases":486,"briefSummary":487,"conditions":488,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":492,"completionDateStruct":493,"leadSponsor":495,"locationsCount":45},"100638727","pilot-study-on-the-clinical-efficacy-of-focused-ultrasound-mediated-targeted-drug-delivery-system-combined-with-neoadjuvant-therapy-for-her2-positive-breast-cancer-100638727","NCT07616440","Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer","Inclusion Criteria:\n\n1. Female patients aged 18-70 years.\n2. Histologically confirmed HER2 positive breast cancer, with indication for neoadjuvant chemotherapy, and scheduled to receive the T(P)CbHP neoadjuvant regimen.\n3. TNM stage T2N0-2M0.\n4. Adequate bone marrow reserve (ANC \\>1.5×10⁹\u002FL, platelets \\>100×10⁹\u002FL).\n5. Normal liver function (ALAT, ASAT, and bilirubin \\\u003C2.5× upper limit of normal).\n6. Adequate renal function (creatinine clearance \\>50 mL\u002Fmin).\n7. Left ventricular ejection fraction (LVEF) ≥50% measured by echocardiography or MUGA.\n8. No psychological, family, social, or geographical conditions that would compromise compliance with the study protocol and follow-up schedule.\n9. No medical conditions that would place the subject at undue risk.\n10. Written informed consent signed by the subject.\n\nExclusion Criteria:\n\n1. Prior history of radiotherapy or chemotherapy.\n2. Pregnant or lactating patients.\n3. Presence of distant metastasis.\n4. Bilateral invasive breast cancer.\n5. Concurrent administration of other anticancer therapies or another investigational agent.\n6. inadequate physical tolerance, including significant cardiovascular, hepatic, or renal dysfunction, massive ascites, intestinal obstruction, severe infection, high fever, as well as water-electrolyte and acid-base imbalance.\n7. Patients with known hyper sensitivity to SonoVue®.","FEMALE",{"count":348,"type":22},[104],"This study aimed to evaluate the feasibility and safety, and to observe early efficacy signals of the focused ultrasound mediated drug delivery system combined with SonoVue® in patients with HER2-positive breast cancer receiving neoadjuvant therapy by comparing its pathological complete response (pCR) rate with a matched historical cohort of HER2-positive breast cancer patients treated at our center.",[489],"HER2-positive Breast Cancer","2026-06-02",{"date":470,"type":37},{"date":155,"type":37},{"date":494,"type":22},"2027-01-31",{"name":43,"class":44},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":503,"targetDuration":4,"studyType":23,"phases":505,"briefSummary":506,"conditions":507,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":509,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":515},"100637588","24-week-recurrence-rate-of-gout-following-firsekibart-treatment-100637588","NCT07625514","24-Week Recurrence Rate of Gout Following Firsekibart Treatment","The 24-Week Recurrence Rate of Acute Gouty Arthritis in Patients Treated With Firsekibart: A Multicenter, Prospective, Real-World Study","Inclusion Criteria:\n\n1. Age 18 to 75 years (inclusive), male or female;\n2. Meet the 2015 ACR\u002FEULAR Gout Classification Criteria;\n3. Two or more acute gout flares within a year;\n4. In the acute phase of a gout flare;\n5. Voluntarily signed the Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n1. History of hypersensitivity to the study drug or similar classes of drugs;\n2. Pregnant or breastfeeding women;\n3. History of clinically significant diseases, including: Chronic congestive heart failure (NYHA Class IV); History of echocardiography-confirmed ejection fraction (EF) \\\u003C 30%; Myocardial infarction, acute coronary syndrome, viral myocarditis, or pulmonary embolism within 6 months; Coronary revascularization within 6 months; Severe arrhythmia requiring treatment with Class Ia or III antiarrhythmic drugs;History of sick sinus syndrome, Mobitz II and Complete Heart Block without a permanent pacemaker implanted; QTc interval≥480 ms on screening ECG ;\n4. Confirmed active tuberculosis infection;\n5. History of severe immunodeficiency, including positive human immunodeficiency virus (HIV) antibody, or other acquired or congenital immunodeficiency diseases;\n6. Presence of infection requiring systemic treatment within 7 days prior to screening;\n7. Laboratory abnormalities at screening as follows: White blood cellcount or absolute neutrophil count below the lower limit of normal at the study site; Platelet count ≤100×10\\^9\u002FL; Total bilirubin \\> 1.5 times ULN (Upper Limit of Normal); AST\u002FALT \\> 3 times ULN; Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73m²; Triglycerides \\> 5.7 mmol\u002FL;\n8. Any other conditions that, in the opinion of the investigator, may affect the evaluation of efficacy or safety in this study.",{"count":504,"type":22},264,[104],"Study Objective: To evaluate the 24-week recurrence rate and safety of Firsekibart in patients with acute gouty arthritis in a real-world clinical setting.\n\nStudy Methods: This study utilizes a multicenter, prospective, observational, real-world study design. The study plans to enroll all cases that receive Firsekibart for the first time and meet the inclusion and exclusion criteria between March 1, 2026, and February 28, 2029, with a follow-up period of 24 weeks. This study will not intervene in clinical treatment regimens; it will solely record and analyze the diagnosis and treatment data that actually occur.\n\nStudy Outcomes: Primary Outcome: The proportion of patients with at least one gout recurrence (flare) at 24 weeks.Secondary Outcomes: 1. Average number of gout recurrences over 24 weeks; 2. Time to the first gout recurrence; 3. Duration of the first gout recurrence; 4. Incidence of adverse events (AEs) and serious adverse events (SAEs).",[508],"Gout Flare",{"date":470,"type":37},{"date":511,"type":22},"2026-05-07",{"date":513,"type":22},"2029-08-28",{"name":43,"class":44},11,{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":522,"targetDuration":4,"studyType":23,"phases":523,"briefSummary":524,"conditions":525,"keywords":527,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":531,"startDateStruct":532,"completionDateStruct":533,"leadSponsor":535,"locationsCount":4},"100617240","construction-and-evaluation-of-an-intelligent-decision-system-for-reperfusion-therapy-in-acute-ischemic-stroke-100617240","NCT07316049","Construction and Evaluation of an Intelligent Decision System for Reperfusion Therapy in Acute Ischemic Stroke","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Clinical diagnosis of acute ischemic stroke (AIS).\n* Presentation within 24 hours of symptom onset or last-known-well.\n* Evaluated for reperfusion therapy (intravenous thrombolysis and\u002For endovascular treatment).\n\nExclusion Criteria:\n\n* Absence of key clinical or imaging data necessary for analysis.\n* Patients not undergoing reperfusion assessment or outside the pre-defined workflow.\n* Prior participation in other AI-based decision support trials within the past 12 months.\n* Explicit refusal of data use or withdrawal of consent (if applicable).",{"count":358,"type":22},[104],"This multicenter, cluster-randomized controlled trial will evaluate the effectiveness and safety of the LingBao System, an AI-enabled clinical decision support platform for reperfusion therapy in acute ischemic stroke (AIS). Twenty certified stroke centers will be randomized 1:1 to LingBao-assisted care or standard care. Consecutive patients aged 18 years or older who present within 24 hours of symptom onset or last-known-well and are evaluated for intravenous thrombolysis and\u002For endovascular therapy will be prospectively enrolled.\n\nThe study initially plans to enroll approximately 3,000 patients from about 20 certified stroke centers, with approximately 150 patients per center. Because this is a cluster-randomized trial, a pre-specified blinded sample size re-estimation will be performed after approximately 40% of participants have completed the 90-day mRS assessment. The re-estimation will be based only on pooled, blinded information, including cluster size, cluster-size variability, intracluster correlation, follow-up completeness, missingness of the primary outcome, and the overall distribution of the 90-day mRS. No between-group treatment effect will be examined, and any sample size adjustment will only allow an increase in enrollment.\n\nAt intervention sites, clinicians may use the LingBao System during their routine workflows. The platform integrates routinely available clinical and imaging data, automatically estimates onset-to-treatment windows, screens contraindications, and provides evidence-based, guideline-concordant recommendations for reperfusion therapy; all treatment decisions remain at physician discretion.\n\nThe primary endpoint is the 90-day modified Rankin Scale (mRS) score analyzed by ordinal shift. Secondary endpoints include workflow metrics (door-to-needle time and door-to-puncture time), reperfusion treatment rates, early neurological improvement, symptomatic intracranial hemorrhage, and mortality.\n\nThe findings will provide real-world evidence on the clinical value of AI-assisted decision support for reperfusion therapy in AIS and inform broader implementation of intelligent stroke management systems.",[526],"Acute Ischemic Stroke",[528,529,530],"Reperfusion Therapy","Artificial Intelligence","Clinical Decision Support System",{"date":470,"type":37},{"date":382,"type":22},{"date":534,"type":22},"2027-02-28",{"name":43,"class":44},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":542,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":544,"targetDuration":4,"studyType":23,"phases":546,"briefSummary":547,"conditions":548,"keywords":550,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":45},"100617159","laparoscopic-versus-open-surgery-for-colon-cancer-with-visceral-obesity-100617159","NCT07314996","Laparoscopic Versus Open Surgery for Colon Cancer With Visceral Obesity","A Randomized Controlled Trial of Laparoscopic Versus Open Surgery for Colon Cancer With Visceral Obesity","LOVO","Inclusion Criteria:\n\n1. Body Roundness Index (BRI) ≥ 5.0, with no laparoscopic surgery contraindications as assessed by the surgeon;\n2. Pathologically confirmed colon adenocarcinoma, mucinous adenocarcinoma, or signet ring cell carcinoma;\n3. Tumor lower edge \\> 12 cm from the anus as measured by colonoscopy, and the tumor lower edge not directly palpable by digital rectal examination;\n4. Single primary lesion;\n5. Aged 18 (inclusive) to 75 (inclusive) years;\n6. Clinical stage T3\u002F4Nany or T1-4N+ on chest non-contrast CT and abdominal enhanced CT, no distant metastasis, and resectable as judged by the surgeon;\n7. Treatment-naive, no prior anti-tumor treatment;\n8. Completed blood routine, liver and kidney function tests, carcinoembryonic antigen (CEA), and carbohydrate antigen 199 (CA199) before randomization, with American Society of Anesthesiologists (ASA) score ≤ III;\n9. Patient able to understand the study protocol and willing to participate in the study.\n\nExclusion Criteria:\n\n1. Height and waist circumference data are unavailable;\n2. Hereditary colorectal cancer (Lynch syndrome or Familial Adenomatous Polyposis \\[FAP\\]);\n3. History of previous malignant neoplasm, with the exception of basal cell carcinoma\u002Fpapillary thyroid carcinoma\u002Fvarious types of in situ cancers\u002Fmicro-invasive early-stage lung cancer;\n4. Acute exacerbation of major organ diseases (such as, but not limited to, COPD, coronary heart disease, and renal insufficiency) and\u002For severe acute infectious diseases (such as, but not limited to, hepatitis, pneumonia, and myocarditis);\n5. The tumor presents with obstruction or is at high risk of obstruction, and\u002For there is bleeding and\u002For perforation, which may necessitate emergency surgery;\n6. Pregnancy or breastfeeding;\n7. Inability to undergo contrast-enhanced CT scan;\n8. Additional surgery after EMR or ESD;\n9. Patients with unremitted severe mental illness, moderate or above cognitive impairment (MMSE ≤ 23 points), or those who have been hospitalized due to mood disorders in the past year or have unstable antipsychotic medication;\n10. Patients with enlarged mesenteric root lymph nodes detected by preoperative CT or intraoperative exploration and suspected metastasis, or suspected metastasis in organs such as peritoneum or liver detected by intraoperative exploration;\n11. Patients with a history of major abdominal surgery and severe adhesions precluding laparoscopic surgery upon laparoscopic exploration.",{"count":545,"type":22},664,[104],"This study aims to elucidate whether there is a difference in long-term prognosis between laparoscopic surgery and open surgery in colon cancer patients with visceral obesity.",[549],"Colonic Neoplasms",[551,552,553,554,555,556],"laparoscopic surgery","open surgery","Body Round Index (BRI)","complete mesocolic excision","oncologic outcome","specimen quality",{"date":558,"type":37},"2026-06-03",{"date":560,"type":37},"2026-01-18",{"date":562,"type":22},"2033-12-31",{"name":43,"class":44},""]